Showing 1541-1550 of 2656 results for "".
- First Patient Dosed in Study of Moderna’s mRNA Vaccine Against COVID-19https://modernod.com/news/first-patient-dosed-in-study-of-modernas-mrna-vaccine-against-covid-19/2477403/Moderna announced that the first subject has been dosed in a phase 1 study of its experimental mRNA vaccine mRNA-1273 against SARS-CoV-2. The phase 1 trial, which is being conducted by the US National Institutes of Health (NIH) at Kaiser Permanente Washington Health Research Institute in Seattle,
- Regeneron’s Novel COVID-19 Antibody Program Has Potential to Enter Human Clinical Studies by Early Summerhttps://modernod.com/news/regenerons-novel-covid-19-antibody-program-has-potential-to-enter-human-clinical-studies-by-early-summer/2477404/Regeneron Pharmaceuticals announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated
- Analysts Give Gilead’s Remdesivir 50% Chance of Success as COVID-19 Treatmenthttps://modernod.com/news/analysts-give-gileads-remdesivir-50-chance-of-success-as-covid-19-treatment/2477362/Analysts at RBC Capital Markets suggested that it is a toss-up whether Gilead Sciences’ remdesivir will succeed in demonstrating efficacy and ultimately securing approval to treat COVID-19, citing limited dosing results, confounding data and previous disappointments in Ebola. “[The] b
- Bausch + Lomb and TerraCycle Partner to Launch Canada’s First and Only Contact Lens Recycling Programhttps://modernod.com/news/bausch-lomb-and-terracycle-partner-to-launch-canadas-first-and-only-contact-lens-recycling-program/2477265/Bausch + Lomb announced that it has partnered with international recycling company TerraCycle to launch the Bausch + Lomb Every Contact Counts recycling program in select eye care offices across Canada. Through the joint initiative, Canadians who wear conta
- Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma’s Impact on Daily Livinghttps://modernod.com/news/allergan-teams-up-with-super-bowl-mvp-von-miller-to-raise-awareness-of-glaucomas-impact-on-daily-living/2477236/Allergan announced a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker, and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the ‘My Glaucoma’ campaign, Mr. Miller wil
- Analysis: FDA’s Efforts to Speed Drug Approval May Have Led to Less Rigorous Clinical Outcome Requirementshttps://modernod.com/news/analysis-fdas-efforts-to-speed-drug-approval-may-have-led-to-less-rigorous-clinical-outcome-requirements/2477231/An analysis published in JAMA suggests that efforts by the FDA to speed the development and approval of drugs may have led to a reduction in the amount of evidence available at the time of authorization by the agency and an increase in more surrogate measures. However, the authors noted
- Bausch Health Licenses Novaliq’s NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunctionhttps://modernod.com/news/bausch-health-licenses-novaliqs-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2477185/Bausch Health Companies and Novaliq have announced that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexy
- Positive Phase 3 Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in NEJMhttps://modernod.com/news/positive-phase-3-results-for-genentechs-satralizumab-in-neuromyelitis-optica-spectrum-disorder-published-in-nejm/2477130/Genentech announced that data from SAkuraSky, a pivotal phase 3 study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), were published in the November 27, 2019 online issue of the New England Journal of Medicine (NEJM).
- Understanding the Eye’s ‘Plumbing’ Could Lead to Future Treatments for Glaucoma, Other Diseaseshttps://modernod.com/news/understanding-the-eyes-plumbing-could-lead-to-future-treatments-for-glaucoma-other-diseases/2477092/Scientists in the University of Arizona Department of Physiology have identified a potential molecular mechanism that may hold the key to understanding how pressure is regulated in the eye. Funded by a $2.3 million 5-year grant from the National Institutes of Health (NIH) National Eye Inst
- EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/ema-and-fda-accept-marketing-applications-for-chugais-satralizumab-in-neuromyelitis-optica-spectrum-disorder-nmosd/2477062/Chugai Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab, an anti-interleukin-6 (IL-6) receptor humanized recycling antibody, for the treatment of adult and adolescent patients with neuromyelitis optica spectrum